Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) & Kyntra Bio (NASDAQ:KYNB)

Kyntra Bio (NASDAQ:KYNB) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Kyntra Bio and Petros Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44 million	4.42	$183.45 million	$40.46	0.17
Petros Pharmaceuticals	$5.11 million	0.02	-$8.16 million	($1.64)	-0.00

Kyntra Bio has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kyntra Bio and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Insider & Institutional Ownership

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 12.2% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Kyntra Bio has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Kyntra Bio and Petros Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	2	1	2.60
Petros Pharmaceuticals	0	0	0	0	0.00

Kyntra Bio presently has a consensus target price of $32.50, indicating a potential upside of 362.30%. Given Kyntra Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Petros Pharmaceuticals.

Summary

Kyntra Bio beats Petros Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.